AB 554 — California
Health care coverage: antiretroviral drugs, drug devices, and drug products.
California legislative agenda & upcoming votes California session calendar
Summary
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy. Under existing law, a health care service plan or health insurer is not required to cover all the therapeutically equivalent versions of those drugs without prior authorization or step therapy if at least one is covered without prior authorization or step therapy.
This bill, the Protecting Rights, Expanding Prevention, and Advancing Reimbursement for Equity (PrEPARE) Act of 2025, would instead prohibit a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs, drug devices, or drug products that are medically necessary for the prevention of HIV/AIDS, to prior authorization or step therapy, but would authorize prior authorization or step therapy if at least one therapeutically equivalent version is covered without prior authorization or step therapy. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting drug, drug device, or drug product is not therapeutically equivalent to a long-acting drug, drug device, or drug product with a different duration. The bill would require a plan or insurer that covers non-self-administered antiretroviral drugs, drug devices, or drug products that are approved by the United States Food and Drug Administration (FDA) for the prevention of HIV/AIDS as a medical benefit to also include those non-self-administered antiretroviral drugs, drug devices, or drug products as an outpatient prescription drug benefit.
This bill would require a nongrandfathered health care service plan contract or health insurance policy to provide coverage for antiretroviral drugs, drug devices, or drug products that are approved by the FDA for HIV preexposure prophylaxis, and would prohibit a nongrandfathered health care service plan contract or health insurance policy from imposing any cost sharing for those drugs, drug devices, or drug products. The bill would prohibit a plan or insurer from imposing cost sharing on a nonformulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered pursuant to an exception request if the nonformulary antiretroviral drug, drug device, or drug product is therapeutically equivalent to a formulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered by the plan or insurer without cost sharing. The bill would exempt Medi-Cal managed care plans from these provisions.
Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
- AB 554 is a bill in the California Assembly, 20252026 session, introduced February 11, 2025.
- Current status: vetoed.
- Most recent action (January 22, 2026): Consideration of Governor's veto stricken from file.
- 8 recorded votes; the most recent, on September 11, 2025, passed 69-1.
- Subjects: Healthcarecoverage, antiretroviraldrugs,drugdevices,anddrugproducts.
Contact your legislator about this bill
Bill text & documents
- AB554 (opens in a new tab)
- 02/11/25 - Introduced (opens in a new tab)
- 03/03/25 - Amended Assembly (opens in a new tab)
- 05/23/25 - Amended Assembly (opens in a new tab)
- 06/24/25 - Amended Senate (opens in a new tab)
- 07/17/25 - Amended Senate (opens in a new tab)
- 09/04/25 - Amended Senate (opens in a new tab)
- 09/12/25 - Enrolled (opens in a new tab)
- 04/26/25- Assembly Health (opens in a new tab)
- 05/07/25- Assembly Health (opens in a new tab)
- 05/12/25- Assembly Appropriations (opens in a new tab)
- 05/28/25- ASSEMBLY FLOOR ANALYSIS (opens in a new tab)
- 07/14/25- Senate Health (opens in a new tab)
- 08/15/25- Senate Appropriations (opens in a new tab)
- 08/29/25- Sen. Floor Analyses (opens in a new tab)
- 09/08/25- Sen. Floor Analyses (opens in a new tab)
- 09/10/25- ASSEMBLY FLOOR ANALYSIS (opens in a new tab)
- 10/23/25- ASSEMBLY FLOOR ANALYSIS (opens in a new tab)
- This bill on Open States (opens in a new tab)
Sponsors
Cosponsors (6): Mark González, Haney, Wiener, Jackson, Wallis, Ward
History
- Introduced, completed
- Passed Assembly, completed
- Passed Senate, completed
- Sent to Governor, completed
- Vetoed, completed, current stage
- Assembly Read first time. To print.
- Assembly From printer. May be heard in committee March 14.
- Assembly Referred to Com. on HEALTH.
- Assembly From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
- Assembly Re-referred to Com. on HEALTH.
-
Assembly
Do pass and be re-referred to the Committee on [Appropriations]
14 yes 0 no, 2 other Passed, 100% yes
- Assembly From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 29). Re-referred to Com. on APPR.
- Assembly In committee: Set, first hearing. Referred to suspense file.
- Assembly Assembly Rule 63 suspended. (Ayes 51. Noes 16. Page 1644.)
- Assembly From committee: Amend, and do pass as amended. (Ayes 11. Noes 0.) (May 23).
-
Assembly
Read second time and amended. Ordered returned to second reading.
Do pass as amended.: 11 yes 0 no, 4 other Passed, 100% yes
- Assembly Read second time. Ordered to third reading.
-
Assembly
Read third time. Passed. Ordered to the Senate. (Ayes 68. Noes 1. Page 2007.)
Milestone
AB 554 Mark González Assembly Third Reading: 68 yes 1 no, 10 other Passed, 99% yes
- Senate In Senate. Read first time. To Com. on RLS. for assignment.
- Senate Referred to Com. on HEALTH.
- Senate From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH.
-
Senate
Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations]
9 yes 0 no, 2 other Passed, 100% yes
- Senate From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (July 16).
- Senate Read second time and amended. Re-referred to Com. on APPR.
-
Senate
In committee: Referred to suspense file.
Placed on suspense file: 7 yes 0 no Passed, 100% yes
-
Senate
From committee: Do pass. (Ayes 6. Noes 0.) (August 29).
Do pass: 6 yes 0 no, 1 other Passed, 100% yes
- Senate Read second time. Ordered to third reading.
- Senate Read third time and amended. Ordered to second reading.
- Senate Read second time. Ordered to third reading.
-
Senate
Read third time. Passed. Ordered to the Assembly. (Ayes 31. Noes 0. Page 2664.).
Milestone
3rd Reading AB554 Mark González et al. By Cabaldon: 31 yes 0 no, 9 other Passed, 100% yes
- Assembly In Assembly. Concurrence in Senate amendments pending.
- Assembly Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 69. Noes 1. Page 3221.).
-
Assembly
AB 554 Mark González Concurrence in Senate Amendments
69 yes 1 no, 10 other Passed, 99% yes
- Legislature Enrolled and presented to the Governor at 3 p.m.
- Assembly Vetoed by Governor. Milestone
- Assembly Consideration of Governor's veto pending.
- Assembly Consideration of Governor's veto stricken from file. Latest